Tamsulosin with dutasteride
Brand names: Combodart
This fixed-dose combination pairs the alpha-blocker tamsulosin with the 5-alpha-reductase inhibitor dutasteride for moderate-to-severe symptomatic benign prostatic hyperplasia, giving both rapid symptom relief and disease modification.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Tamsulosin relaxes prostatic and bladder-neck smooth muscle via selective alpha-1A adrenoceptor blockade, while dutasteride inhibits type-1 and type-2 5-alpha-reductase to lower dihydrotestosterone and shrink the prostate.
Prescribing in practice
- Dutasteride is teratogenic and absorbed through skin, so the capsules must not be handled by women who are or may become pregnant, and treated men should not donate blood during therapy and for a defined period afterwards.
- Tamsulosin can cause first-dose and postural hypotension and intra-operative floppy iris syndrome, so cataract surgeons must be told the patient is taking it.
- Dutasteride approximately halves prostate-specific antigen, and this must be accounted for when interpreting PSA for prostate cancer screening.
Monitoring
Monitor symptom response, postural blood pressure and PSA trends interpreted against the expected dutasteride-related reduction.
Counselling the patient
- Women who are or could become pregnant must not handle the capsules.
- Rise slowly to avoid dizziness, and tell your eye surgeon you take this before any cataract operation.
Evidence & guidelines
The CombAT trial showed combined tamsulosin and dutasteride reduced symptom progression and acute urinary retention more than either agent alone in larger prostates.
Reference: NICE NG106; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- MAGGIC Heart Failure Risk Score · Heart Failure
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy